Searched for
AFFORDABLE CANCER MEDICINES
Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are backThe government's latest cancer drug price cuts may offer patients some relief, but the impact could be short-lived. An analysis of medicine...- NPPA list brings little relief: No price cut for 25% cancer drugsNearly one in four cancer drug packs in the NPPA’s revised price list will see no reduction in MRP, even as the overall average cut across ...
- India’s drug pricing policy must balance affordability, medicine availability and pharma industry growthThe Government of India has recently capped trade margins on anti-cancer medicines at 30%. This decision has reignited the ongoing discussi...
- Anti-cancer medicines: How to protect the patient today without weakening India's healthcare capacity for tomorrowIndia should examine trade margins across medicines, medical devices and consumables using a common, scientifically credible method - not a...
- India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: PharmexcilIndia's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driv...
- Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...
- The burden of cancer drugs: Millions battle exorbitant prices as life-saving treatment slips out of reachFor millions of cancer patients, the cost of treatment can be as frightening as the diagnosis. From steep markups to patented drugs that re...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
- Apollo, Max Health, other hospital stocks rally up to 5% despite cancer drug price caps. Why Jefferies stays bullishHospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing med...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- Karnataka flags 52x mark-up on cancer drugs, seeks Centre's interventionKarnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs a...
- Kerala HC says exorbitant drug prices can trigger government intervention in patented medicinesThe Kerala High Court ruled that government intervention is permissible for prohibitively priced patented medicines. The court directed the...
- Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in IndiaNovartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, d...
- Biocon shares rise 3% after Rs 638-crore block deal; Active Pine likely sellerBiocon shares rose after a block deal involving around 1.65 crore shares. Investor Active Pine was reportedly looking to sell up to 1.66 cr...
- Biocon shares: Active Pine may divest up to 1% equity worth Rs 638 crore via block dealActive Pine is likely to sell up to 1.66 crore Biocon shares, worth Rs 638 crore, through a block deal at Rs 385 per share. The development...
- Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in BrazilBiocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis re...
- Biocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugIn a significant move, Biocon has secured a ten-year contract in Brazil for the distribution of Pertuzumab, made possible through its colla...
Load More
